Modex’s antibodies contain multiple binding sites and can target several parts of SARS-CoV-2’s spike protein, the tool the ...

Illumina is welcoming a new addition to its DNA sequencing lineup, with a pair of accessible benchtop instruments that ...

Join IQVIA in its Launch Excellence webinar, where we build on our Launch Excellence framework to explore challenges and key drivers of commercial success for new launches. New launches continue ...

Some six years after picking up Seattle’s Universal Cells for $102 million, Astellas Pharma is opening a second location for ...

After putting forward preliminary clinical data earlier this year from its neuromodulation implant for reducing chronic ...

A day after the Physics prize was given to two scientists for foundational work on machine learning, the Nobel Prize in ...

Insitro has teamed up with Eli Lilly to help power programs into the clinic, tapping the Big Pharma for an option on ...

InnoCare Pharma’s tyrosine kinase 2 (TYK2) inhibitor has hit the main goals of a phase 2 trial in China, sustaining the ...

Boehringer Ingelheim has rolled into an alliance with undruggable target specialist Circle Pharma, putting together a package ...

With Kezar Life Sciences’ lupus plans up in the air while the company investigates patient deaths, Concentra Biosciences has ...

London-based biotech Purespring Therapeutics plans to bring their kidney-tweaking gene therapy to the clinic with the help of ...

In another blow to its $525 million buyout of ReViral, Pfizer has ended development of sisunatovir, an oral inhibitor ...